Gapping up
In reaction to strong earnings/guidance: IKGH +20.5%, SLTD +7.2%, FSI +3.9%, RIBT +0.5%, RGSE +0.4%
Select EU notables showing strength: CS +2.7%, BCS +2.4%, NVO +1.9%, SNY +1.8%, DB +1.7%, NVS +1.6%, GSK +1.3%, SAN +1.2%, SAP +1%
Select oil/gas related names showing strength: PBR +2%, STO +1.4%, RDS.A +1.2%, TOT +0.9%
Other news: VLTC +117.8% (Carl Icahn disclosed 52.3% active stake in 13D filing), DYAX +46.2% (announces positive results from Phase 1b Clinical Trial of DX-2930 ), INS +9.4% (signed a Stock Purchase Agreement to sell its ChemFree Corporation subsidiary to CRC Industries, Inc for ~$21.6 mln), SRPT +9.2% (appoints Edward Kaye, M.D., as Interim CEO; company on track with clinical and regulatory plans for investigational duchenne muscular dystrophy drugs), ONVO +9% (presents data on in vitro three-dimensional kidney tissue), NBIX +8% (Neurocrine Biosci and Mitsubishi Tanabe Pharma announce agreement to develop and commercialize VMAT2 inhibitor NBI-98854 for movement disorders in Japan and other select Asian markets), SHLD +6.3% (Sears Hldg and General Growth Properties (GGP) have entered into a real estate JV), CYRN +5.6% (following Mitsubishi / Siemen deal), MDCO +3.6% (announces Angiomax patent litigation settlement with Sun Pharmaceuticals), CBK +3.2% (5.2% holder Macellum delivers letter to the CBK mgmt; urges upgrade of board and exploring potential sale to maximize shareholder value), GBSN +2.8% (cont strength), CHK +2.4% (Chesapeake Energy Chairman disclosed purchase of 1 mln shares, worth total of $13.979 mln ), RUBI +2.1% (reached a definitive agreement to acquire privately held Chango Inc for ~$122 mln; Reaffirms Confidence in Q1 2015 Financial Outlook), PMFG +2.1% (announced agreement to sell its ALCO products and Boss-Hatten heat exchanger brands to Koch Heat Transfer; financial details not disclosed), RCPT +1.9% (completed enrollment in the RADIANCE Phase 3 trial of ozanimod in patients with Relapsing Multiple Sclerosis)
Analyst comments: ESPR +3.7% (initiated with a Buy at UBS), TRVN +2.9% (initiated with a Outperform at Wedbush), SPLS +2.2% (upgraded to Overweight from Sector Weight at Keybanc Capital Mkts), LYG +2.1% (upgraded to Hold from Underperform at Jefferies), PHG +1.7% (added to Conviction Buy List at Goldman), TWTR +1.4% (initiated with a Buy at Jefferies), AMT +1.4% (upgraded to Strong Buy from Outperform at Raymond James; esumed with a Overweight at JP Morgan), HPQ +1% (upgraded to Buy from Hold at Jefferies), ZU +1% (initiated with an Outperform at OPCO)
In reaction to strong earnings/guidance: IKGH +20.5%, SLTD +7.2%, FSI +3.9%, RIBT +0.5%, RGSE +0.4%
Select EU notables showing strength: CS +2.7%, BCS +2.4%, NVO +1.9%, SNY +1.8%, DB +1.7%, NVS +1.6%, GSK +1.3%, SAN +1.2%, SAP +1%
Select oil/gas related names showing strength: PBR +2%, STO +1.4%, RDS.A +1.2%, TOT +0.9%
Other news: VLTC +117.8% (Carl Icahn disclosed 52.3% active stake in 13D filing), DYAX +46.2% (announces positive results from Phase 1b Clinical Trial of DX-2930 ), INS +9.4% (signed a Stock Purchase Agreement to sell its ChemFree Corporation subsidiary to CRC Industries, Inc for ~$21.6 mln), SRPT +9.2% (appoints Edward Kaye, M.D., as Interim CEO; company on track with clinical and regulatory plans for investigational duchenne muscular dystrophy drugs), ONVO +9% (presents data on in vitro three-dimensional kidney tissue), NBIX +8% (Neurocrine Biosci and Mitsubishi Tanabe Pharma announce agreement to develop and commercialize VMAT2 inhibitor NBI-98854 for movement disorders in Japan and other select Asian markets), SHLD +6.3% (Sears Hldg and General Growth Properties (GGP) have entered into a real estate JV), CYRN +5.6% (following Mitsubishi / Siemen deal), MDCO +3.6% (announces Angiomax patent litigation settlement with Sun Pharmaceuticals), CBK +3.2% (5.2% holder Macellum delivers letter to the CBK mgmt; urges upgrade of board and exploring potential sale to maximize shareholder value), GBSN +2.8% (cont strength), CHK +2.4% (Chesapeake Energy Chairman disclosed purchase of 1 mln shares, worth total of $13.979 mln ), RUBI +2.1% (reached a definitive agreement to acquire privately held Chango Inc for ~$122 mln; Reaffirms Confidence in Q1 2015 Financial Outlook), PMFG +2.1% (announced agreement to sell its ALCO products and Boss-Hatten heat exchanger brands to Koch Heat Transfer; financial details not disclosed), RCPT +1.9% (completed enrollment in the RADIANCE Phase 3 trial of ozanimod in patients with Relapsing Multiple Sclerosis)
Analyst comments: ESPR +3.7% (initiated with a Buy at UBS), TRVN +2.9% (initiated with a Outperform at Wedbush), SPLS +2.2% (upgraded to Overweight from Sector Weight at Keybanc Capital Mkts), LYG +2.1% (upgraded to Hold from Underperform at Jefferies), PHG +1.7% (added to Conviction Buy List at Goldman), TWTR +1.4% (initiated with a Buy at Jefferies), AMT +1.4% (upgraded to Strong Buy from Outperform at Raymond James; esumed with a Overweight at JP Morgan), HPQ +1% (upgraded to Buy from Hold at Jefferies), ZU +1% (initiated with an Outperform at OPCO)